EAE. O. Abduraimov

E. O. Abduraimov

*This is an algorithmically generated author record based on publicly available information.

E. O. Abduraimov has a total of 52 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE CLINICAL EFFICACY AND SAFETY OF BACTERIOPHAGES IN BACTERIAL INFECTIONS

    by N.S. Sikhayeva, A.S. Dyussenbekova, K.B. Bekeshova, N.A. Esenbekova, Zh.D. Kanalyn, A.S. Rsaliyev, Y.O. Abduraimov

    The growing number of infections caused by multidrug-resistant bacteria (MDR) makes the development of alternative therapeutic strategies a priority of modern medicine. Bacteriophage therapy is considered as a promising method for the treatment of resistant infections; however, a systematic synthesis of clinical data remains an urgent task. The purpose of this review is to systematically summarize clinical data on bacteriophage therapy in humans and estimate the proportion of patients with clinical improvement. A systematic search was performed in the PubMed/MEDLINE, Embase, and Cochrane CENTRAL databases (January 2000 - February 2026). Randomized controlled trials (RCTs), cohort studies, case series, and compassionate use studies with ≥3 participants were included. Primary outcome – percentage of patients with clinical improvement. The meta-analysis was performed using a random effects model (DerSimonian–Laird method, logit transformation, Hartung–Knapp correction). The risk of systematic error was assessed using the RoB 2 (for RCTs) and ROBINS-I (for non-randomized studies) instruments. The review was carried out in accordance with the PRISMA 2020 guidelines. As a result, the final analysis included 17 studies (683 patients; 9 RCTs, 1 randomized uncontrolled study, and 7 nonrandomized studies) from more than 10 countries. The most studied pathogens were Pseudomonas aeruginosa, Staphylococcus aureus and Escherichia coli. The pooled proportion of patients with clinical improvement was 57.2% (95% CI: 35.9–76.1%; k=8, N=393), with high heterogeneity (I²=88.2%; prediction interval: 10.7–93.7%). In the leave-one-out analysis, the pooled proportion ranged from 52.6% to 63.1%. The reviewed publications did not report any serious adverse events with a confirmed relationship to phage administration. Four RCTs had a low risk of bias. In conclusion, published studies showed acceptable tolerability of bacteriophage therapy, with no reports of phage-related serious adverse events, and evidence suggestive of clinical benefit, particularly as an adjunct to antibiotic therapy for MDR infections. High heterogeneity, the predominance of uncontrolled study designs, and the noncomparative nature of the pooled estimate preclude conclusions about the efficacy of phage therapy relative to standard treatment. Large multicenter RCTs with standardized outcomes and systematic recording of adverse events are needed, along with standardization of the pharmaceutical quality of phage preparations.

  • Open Access

    PRODUCTION OF HYPERIMMUNE SERUM AGAINST ANTHRAX

    by B.K. Umuraliyev, M.S. Seisenbayeva, A.S. Zhakypbek, A.S. Rsaliev, A.A. Isakhan, N.K. Orazymbetova, M.ZH. Kaukarbayeva, K.D. Zhugunisov, Zh.B. Kondibayeva, Zh.K Koshemetov, et al.

    This study presents the results of obtaining a specific hyperimmune serum against the causative agent of anthrax (Bacillus anthracis). As antigenic material, purified and inactivated strains “STI-1”, “78/NIIPBB”, and “Anthrax culture (matrix No. 71, Tsienkovsky’s second vaccine)” were used. To accelerate the production of specific antibodies, various hyperimmunization schemes were tested using sheep, goats, and rabbits. Immunization was carried out with adjuvants of different origins — complete Freund’s adjuvant, aluminum hydroxide, and Montanide ISA-70 — at an antigen-to-adjuvant ratio of 1:1. The dynamics of antibody titer increase were evaluated using diffusion precipitation and indirect hemagglutination assays. It was found that the highest antibody titers were observed in goats and rabbits on the 21st day after immunization, reaching 1:2560, indicating a pronounced immune response when combined antigen administration schemes were applied. The results confirm the efficiency of selecting an optimal hyperimmunization strategy and demonstrate the feasibility of using small laboratory and farm animals for producing specific hyperimmune sera against Bacillus anthracis. These findings provide a foundation for developing rapid and cost-effective methods for the production of specific serum preparations.

  • Open Access

    RESULTS OF MONITORING STUDIES ON SHEEP POX IN KAZAKHSTAN IN 2024

    by A.B. Aliyeva, D.B. Aidarbekova, E.K. Almas, O.N. Serikbayov, K.B. Barakbayev, A.A. Kerimbaev, A.S. Rsaliev, E.O. Abduraymov

    This study presents the results of sheep pox monitoring conducted by the Research Institute for Biological Safety Problems (RIBSP) in the Republic of Kazakhstan. To study the epizootic situation of sheep pox, several field expeditions were organized to 15 regions of the country. The primary objectives of the monitoring were to assess the prevalence of the sheep pox virus among small ruminants, identify potential infection foci, and analyze the level of animal immunity. This is due to the paramount importance of controlling the epizootic situation, timely detection of outbreaks, and development of veterinary and sanitary measures for forecasting the spread of sheep pox. The samples were collected from 240 rural districts within 82 rayons (or settlements/farms) across 15 regions of Kazakhstan: Zhambyl, Karaganda, Kyzylorda, Turkestan, Almaty, Zhetysu, Abay, Akmola, West Kazakhstan, Aktobe, North Kazakhstan, East Kazakhstan, Pavlodar, Atyrau, and Mangystau. Sheep blood serum samples were analyzed by enzyme-linked immunosorbent assay (ELISA) for antibodies to the sheep pox virus. The monitoring revealed an uneven distribution of immune animals to the sheep pox virus in Kazakhstan. In the Abay, East Kazakhstan, Aktobe, and Pavlodar regions, no serologically positive animals were detected, indicating the absence of post-vaccination immunity. A low level of immunity was registered in the Akmola, Karaganda, West Kazakhstan, North Kazakhstan, Mangystau, and Atyrau regions. In contrast, the Zhambyl, Turkestan, Almaty, and Zhetysu regions demonstrate the presence of an immune background against sheep pox.


  • Open Access

    SCALING COWPOX VACCINE PRODUCTION TECHNOLOGY: FROM DEVELOPMENT TO GMP STANDARDS

    by Назым Есимбекова, Жугунисов К.д., Кайсенов Д.н., Кожамкулов Е.м., Исмагамбетов Б.м., Абдураимов Е.о., Рсалиев А.с. А.с., Сихаева Н.с. Н.с., Ершебулов З.д.

    This paper presents a comprehensive analysis and systematization of the key stages of scaling the technological chain of production of cowpox vaccine, with an emphasis on the full-scale adaptation of production processes to strict criteria of good manufacturing practice (GMP). Special attention is paid to the detailed validation of all key stages, including virus cultivation, vaccine formation, lyophilization process and comprehensive quality control of the final product. Validation of key processes was carried out with careful elaboration of virus culture protocols, which included the use of the Nunc Cell Factory, ensuring high stability and reproducibility of the procedure. The introduction of improved methods of microbiological purity control at all stages of production, including regular checks for the presence of microorganisms and monitoring of environmental parameters, contributed to improving the reliability of the production process. Operational standardization was achieved through the integration of real-time systems for data monitoring and analysis, which helped minimize human error and improve production accuracy. As a result, key optimization strategies have been identified and implemented to improve production efficiency, including improving automation processes and digitalizing production lines. The results of the study represent a significant step forward in the development of veterinary vaccinology, providing a reliable basis for future developments and innovations in the field of prevention and treatment of infectious diseases in farm animals. The work highlights the importance of an interdisciplinary approach combining biological, engineering, and management competencies to achieve high standards of vaccine quality and safety. In light of the emerging challenges associated with changes in legislation and the development of new technologies, this work offers a platform for continuing research in the field of biotechnology and vaccine production aimed at adapting to the dynamic conditions of the veterinary industry.

  • Open Access

    OBTAINING SPECIFIC ANIMAL BLOOD SERUM TO THE CAUSATIVE AGENT OF EPIZOOTIC LYMPHANGOITIS IN EQUINES

    by E.O. Abduraimov, M.ZH. Kaukarbaeva, A.S. Rsaliev, B.K. Umuraliev, A.A. Isakhan, N.K. Orazimbetova, Kh.B. Abeuov, Zh.B. Kondibaeva, Zk.K. Koshemetov, A.S. Zhakypbek, et al.

    Selection of animals for obtaining specific blood serums is an important step. Before the start of immunization, blood samples were taken from potential donors for testing using enzyme-linked immunosorbent assay (ELISA), diffusion precipitation reaction (DPR) and prolonged complement fixation reaction (PCFR) to detect antibodies to other viral and bacterial infections. It has been experimentally established that antibodies to the pathogens of equine epizootic lymphangitis (ELL), peste des petits ruminants, sheep pox and anthrax were not detected in the blood serum of rabbits, goats and sheep used to obtain specific blood serum. This is necessary to exclude possible cross-reactions when using the obtained immune sera in serological reactions. To obtain specific sera in the experiment, purified antigens of the cultures of strains “T”, “3724 K” and “3730 K” of the causative agent of ELL were used, which have activity in the RDP within the range of 1:16-1:32 and in the RSC of at least 1:40-1:80. To obtain a specific serum, 11 immunization schemes were tested, which differed in the methods of immunization, the concentration and volume of the administered antigen, the intervals between administrations, and the different strains of diseases used to administer them. Experimentally, we managed to obtain specific and active serums from rabbits, goats and sheep. The activity of immune serums in rabbit #6 DPR was 1:32, in PCFR – 1:128, goat #1 in DPR – 1:16, in PCFR 1:64 and sheep #1 in DPR 1:8, in PCFR 1:32. These diagnostic serums will be used to establish laboratory methods for detecting the antigen of the ELL pathogen in the biological materials being studied.


  • Open Access

    DETERMINATION OF EFFECTIVE PARAMETERS FOR THE CULTIVATION OF A STRAIN OF BOVINE WARTY DERMATITIS VIRUS «DERMATITIS NODULARIS BOVUM/ 2018/ KOSTANAY / KZ»

    by A. Zh. Ragatova, E. O. Abduraimov

    The article presents the results of studies on the cultivation of lumpy skin disease virus in cell cultures obtained from the kidney and testicle of a lamb, the kidney of an embryonic cattle (MDBK), the kidney of a newborn Syrian hamster (BHK-21), the kidney of an African green monkey (Vero) and the determination of optimal cultivation parameters of the strain of this virus in the selected cell culture. According to the results of the research, it was found that among the tested cell cultures obtained from the kidneys and testicles of lambs, they showed high sensitivity to the cultivation of this virus. Also, as a result of the research, the optimal parameters for cultivating the virus in cell culture were determined, including the infecting dose - 0.1÷0.001 TCD50/cell; the optimum cultivation temperature is 36.5°C; serum content in the composition of the nutrient medium - 2%; cultivation period 96-144 hours. Based on these established optimal cultivation parameters, the infectious activity of this strain ranged from 106.10 to 106.25 lg TCID50/cm3. In addition, during the holding of the virus in trypsinized primary cell cultures for up to 10 successive passage generations, the virus adapts to the specified cell, causing cytopathological changes in the cell, which also made it possible to obtain the maximum viral mass. The obtained results of the research can be widely used in the future in the development of preventive and diagnostic drugs against the lumpy skin disease virus CRS.

  • Determining optimal conditions for growing recombinant vectors to be used in developing a bovine tuberculosis vaccine

    by Ainur Nurpeisova, Zhandos Abay, Kamshat Shorayeva, Sandugash Sadikaliyeva, Bolat Yespembetov, Kuanish Jekebekov, Nazym Syrym, Elina Kalimolda, Makhpal Sarmykova, Kunsulu Zakarya, et al.

    Two recombinant influenza A virus vectors expressing the ESAT 6 and TB10.4 mycobacterial proteins from the nonstructural (NS) gene were constructed via reverse genetics technique to develop a specific means of prophylaxis for bovine tuberculosis. We experimented to determine optimal conditions for growing recombinant vectors in Vero cell culture and chick embryos. This study established that the maximum amount of virus builds up in a Vero cell culture with the Dulbecco′s Modified Eagle′s Medium (DMEM) serum-free medium. However, using cell culture to produce vector vaccines is labourintensive and inefficient. An alternative way, a traditional, time-tested technique, is provided by growing samples in chick embryos. One of the advantages of this technique is its affordability and availability, enabling easy scale-up of vaccine production. In the optimization experiments, the FLU-ΔNS_ESAT 6 and FLU-ΔNS_ТВ10.4 viruses constructed were inoculated into 10-day-old chick embryos. It was determined that the optimal incubation temperature that led to the highest virus build-up was 37 ± 0.5 °С. And the infectious activity level of the FLU-ΔNS_ESAT 6 recombinant vector was at 8.95 ± 0.07 log10EID50 0.2 cm-3, while that of the FLU-ΔNS_ТВ10.4 was at 9.20 ± 0.07 log10EID50 0.2 cm-3, what was provided by infectious doses of 1000–10000 EID50, which makes it possible to create a virus-containing material with a hemagglutination activity level of 1:64. The size of recombinant vector amplicons expressing proteins ТВ10.4 and ESAT 6 was 1170 bp and 1175 bp, respectively. Electron microscopy images confirm that the developed virions are morphologically similar to the avian influenza virus.

  • Open Access

    ANALYSIS OF APPROACHES OF INDIVIDUAL ASIAN COUNTRIES TO ASSESS BIOLOGICAL RISKS

    by N. S. Sikhayeva, A. A. Adilova, A. B. Danebayev, M. E. Kisykova, B. B. Abit, Zh. P. Nurbekov, K. D. Zakarya, E. O. Abduraimov, A. S. Rsaliyev

    Оver the past decade, the increase in outbreaks of infectious diseases such as COVID-19, monkeypox, etc. has forced us to reconsider the approach to assessing biological risks in ensuring biological safety. The rapid global spread of these diseases is putting enormous pressure on governments and international agencies to diagnose, treat and control outbreaks. In this regard, it is necessary to study their potential in the field of biosecurity, including the diagnosis, treatment, and research of infectious diseases and improve the rules and guidelines for biodefense. An analysis of foreign experience, including China, Pakistan, Kyrgyzstan, Tajikistan and Kazakhstan was carried out on biological risk assessment, which requires constant monitoring and assessment of emerging threats and evolving risks. Monitoring includes conducting regular infectious disease surveillance, analyzing trends and patterns of disease transmission, and evaluating the effectiveness of prevention and control measures. Countries can adapt their approaches and strategies to address new and emerging threats by continuously monitoring and reassessing biological risks. In conclusion, the experience of foreign countries in biological risk assessment provides valuable information on best practices, strategies and technologies that can help improve global biological risk management and mitigation efforts. This review article highlights the importance of reliable surveillance systems, effective communication and cooperation, investment in research and development, constant vigilance and preparedness for biological threats.